Century Begin Period Cash Flow from 2010 to 2025
| IPSC Stock | USD 0.55 0.01 1.79% |
Begin Period Cash Flow | First Reported 2020-03-31 | Previous Quarter 41.5 M | Current Value 55.4 M | Quarterly Volatility 56.6 M |
Check Century Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Century Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 32.4 M or Total Revenue of 6.3 M, as well as many indicators such as Price To Sales Ratio of 11.45, Dividend Yield of 0.0 or PTB Ratio of 0.52. Century financial statements analysis is a perfect complement when working with Century Therapeutics Valuation or Volatility modules.
Century | Begin Period Cash Flow |
Latest Century Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Century Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Century Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Century Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Century Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 39,636,078 | |
| Geometric Mean | 37,522,925 | |
| Coefficient Of Variation | 39.43 | |
| Mean Deviation | 11,753,607 | |
| Median | 31,424,000 | |
| Standard Deviation | 15,628,593 | |
| Sample Variance | 244.3T | |
| Range | 58.5M | |
| R-Value | 0.65 | |
| Mean Square Error | 150T | |
| R-Squared | 0.43 | |
| Significance | 0.01 | |
| Slope | 2,145,001 | |
| Total Sum of Squares | 3663.8T |
Century Begin Period Cash Flow History
About Century Therapeutics Financial Statements
Century Therapeutics stakeholders use historical fundamental indicators, such as Century Therapeutics' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Century Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Century Therapeutics' assets and liabilities are reflected in the revenues and expenses on Century Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Century Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 49.3 M | 54.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Century Therapeutics Correlation against competitors. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.61) | Revenue Per Share | Quarterly Revenue Growth 14.571 | Return On Assets | Return On Equity |
The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.